Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC’s Stern POM Opinion Expands Disease Claim Findings

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission’s 5-0 decision against POM Wonderful finds the firm made false and misleading claims and requires it to conduct at least two randomized controlled clinical trials for all future disease-related claims. POM vows to appeal the order in federal court.

Advertisement

Related Content

Supreme Court Slays POM Wonderful's Appeal Of FTC Order
FTC Homeopathic Meeting Features Tort Attorney, Commissioner Critical Of Enforcement
FTC Members Spar Over ‘Protected’ Speech On ‘Dr. Oz’ In Supplement Claims Enforcement
POM Decision Will Free FTC Resources For Other Enforcement
POM Wonderful Says Interviews Fall Outside FTC Advertising Scope

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel